Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2Myeloid 1

Conditions

Multiple Myeloma 55Neoplasms, Plasma Cell 22Central Nervous System Neoplasms 10Prostatic Neoplasms 9Glioblastoma 9Recurrence 8Melanoma 8Brain Neoplasms 8Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Leukemia 6Carcinoma, Hepatocellular 6Waldenstrom Macroglobulinemia 5Myeloproliferative Disorders 5Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Colorectal Neoplasms 5Myelodysplastic-Myeloproliferative Diseases 4Myelodysplastic Syndromes 4Lymphoma 4Liver Neoplasms 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3

Interventions

Cyclophosphamide 23Cyclosporine 17Busulfan 16fludarabine phosphate 14Radiotherapy 12Mycophenolic Acid 12Cord Blood Stem Cell Transplantation 12Antilymphocyte Serum 12Peripheral Blood Stem Cell Transplantation 11Whole-Body Irradiation 10Methotrexate 8Methylprednisolone 7Tacrolimus 6Filgrastim 6Melphalan 5fludarabine 4sargramostim 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Cytarabine 3Cyclosporins 3merphos 2Transplantation 2Thiotepa 2Thalidomide 2Arsenic Trioxide 2vatalanib 1paricalcitol 1lintuzumab 1gamma-Globulins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Anemia, Refractory × Thalidomide × Clear all
NCT00030550 2013-01-31

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Roswell Park Cancer Institute

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00015990 2013-01-24

Thalidomide in Treating Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Completed
29 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡